Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.82 |
| ▸ | SCD | O00767 | 10/20 | 0.70 |
| ▸ | GSK3B | P49841 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064488 | 0.90 | HDAC1 (1.00) | HDAC1SCDMEN1RAB9AKMT2A | |
| SCHEMBL210775 | 0.88 | HDAC1 (0.73) | HDAC1SCDMEN1RAB9AKMT2A | |
| SCHEMBL214339 | 0.84 | HDAC1 (0.75) | HDAC1SCDMEN1RAB9AKMT2A | |
| SCHEMBL213883 | 0.83 | GSK3B (0.78) | SCDGSK3BMEN1RAB9AKMT2A | |
| SCHEMBL16562069 | 0.82 | SCD (1.00) | HDAC1SCDMEN1RAB9AKMT2A | |
| SCHEMBL6058245 | 0.79 | GSK3B (0.73) | SCDGSK3BMEN1RAB9AKMT2A | |
| SCHEMBL211854 | 0.79 | HDAC1 (0.78) | HDAC1SCDMAPTSMN1; SMN2 | |
| SCHEMBL16562258 | 0.79 | SCD (0.81) | SCDMEN1RAB9AKMT2ANPC1 | |
| SCHEMBL15685080 | 0.79 | HDAC1 (0.67) | HDAC1 | |
| SCHEMBL210479 | 0.78 | HDAC1 (0.77) | HDAC1SCDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885SCD 1653/4885GSK3B 392/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885SCD 1721/4885GSK3B 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.